BioNTech SE (BNTX) has released an update.
BioNTech SE, in partnership with its AI subsidiary InstaDeep, is revolutionizing immunotherapy by scaling and integrating advanced AI technologies into its pipeline. At the inaugural AI Day, the company showcased its cutting-edge AI advancements, including a near exascale supercomputer and novel AI models, aimed at enhancing the development of personalized vaccines and targeted cancer treatments. Through collaborations and its own expertise, BioNTech is set to accelerate innovation in the biotech industry.
For further insights into BNTX stock, check out TipRanks’ Stock Analysis page.
